Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 4/2019

01-04-2019 | Original Article

Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer

Authors: Yasunori Yoshino, Ayumi Taguchi, Maki Takao, Tomoko Kashiyama, Akiko Furusawa, Masaya Uno, Satoshi Okada, Nao Kino, Toshiharu Yasugi

Published in: International Journal of Clinical Oncology | Issue 4/2019

Login to get access

Abstract

Background

Lymphopenia is associated with poor outcomes in patients with various cancers, but little is known about the prognostic impact of lymphopenia in patients with epithelial ovarian cancer (EOC) after induction chemotherapy (IC). This study investigated the prognostic significance of pre- and post-IC lymphopenia in patients with advanced EOC.

Methods

We reviewed medical records of 68 patients with stage III/IV ovarian, fallopian tube, or peritoneal cancer treated with IC at our institution between 2009 and 2017. We assessed the associations of pre- and post-IC inflammatory markers, including lymphocyte counts, with several oncological outcomes, such as the implementation of interval debulking surgery (IDS), complete resection, progression-free survival (PFS), and overall survival (OS).

Results

Lymphocyte counts increased significantly post-IC compared with the pre-IC values (P = 0.009). Pre-IC lymphopenia was observed in 27 patients (40%), whereas only 16 patients (24%) displayed lymphopenia post-IC (P = 0.020). Among several inflammatory markers, only post-IC lymphopenia was significantly associated with incomplete resection outcome during IDS (P = 0.012). Moreover, post-IC lymphopenia was significantly associated with poor PFS (log-rank test, P = 0.009), whereas pre-IC lymphopenia was associated with neither PFS nor OS.

Conclusions

Post-IC lymphopenia may predict incomplete resection during IDS and poor prognosis in patients with advanced EOC.
Literature
1.
2.
Morgan RJ Jr, Armstrong DK, Alvarez RD et al (2016) Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 14:1134–1163CrossRef
3.
Auersperg N, Wong AS, Choi KC et al (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22:255–288PubMed
4.
Elattar A, Bryant A, Winter-Roach BA et al (2011) Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 8:CD007565
5.
Bowen RC, Little NAB, Harmer JR et al (2017) Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. Oncotarget 8:32171–32189CrossRefPubMedCentralPubMed
6.
Koh CH, Bhoo-Pathy N, Ng KL et al (2015) Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer 113:150–158CrossRefPubMedCentralPubMed
7.
Kang MH, Go SI, Song HN et al (2014) The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer 111:452–460CrossRefPubMedCentralPubMed
8.
Taguchi S, Nakagawa T, Matsumoto A et al (2015) Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: a multi-institutional study. Int J Urol 22:638–643CrossRefPubMed
9.
Kim YJ, Lee I, Chung YS et al (2018) Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer. Obstet Gynecol Sci 61:227–234CrossRefPubMedCentralPubMed
10.
Marchetti C, Romito A, Musella A et al (2018) Combined Plasma Fibrinogen and Neutrophil Lymphocyte Ratio in Ovarian Cancer Prognosis May Play a Role? Int J Gynecol Cancer 28:939–944CrossRefPubMed
11.
Williams KA, Labidi-Galy SI, Terry KL et al (2014) Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol 132:542–550CrossRefPubMedCentralPubMed
12.
Diakos CI, Charles KA, McMillan DC et al (2014) Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15:493–503CrossRef
13.
Galon J, Angell HK, Bedognetti D et al (2013) The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39:11–26CrossRefPubMed
14.
Gooden MJ, de Bock GH, Leffers N et al (2011) The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 105:93–103CrossRefPubMedCentralPubMed
15.
Tomšová M, Melichar B, Sedláková I et al (2008) Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 108:415–420CrossRefPubMed
16.
Lo CS, Sanii S, Kroeger DR et al (2017) Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin Cancer Res 23:925–934CrossRefPubMed
17.
Pölcher M, Braun M, Friedrichs N et al (2010) Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma. Cancer Immunol Immunother 59:909–919CrossRefPubMed
18.
Milne K, Alexander C, Webb JR et al (2012) Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med 10:33CrossRefPubMedCentralPubMed
19.
Campian JL, Ye X, Brock M et al (2013) Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Investig 31:183–188CrossRef
20.
Ray-Coquard I, Cropet C, Van Glabbeke M et al (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69:5383–5391CrossRefPubMedCentralPubMed
21.
d’Engremont C, Vernerey D, Pointet AL et al (2016) Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study. BMC Cancer 16:823CrossRefPubMedCentralPubMed
22.
Liu LT, Chen QY, Tang LQ et al (2018) The prognostic value of treatment-related lymphopenia in nasopharyngeal carcinoma patients. Cancer Res Treat 50:19–29CrossRefPubMed
23.
Kou F, Lu Z, Li J et al (2016) Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy. Cancer Med 5:778–786CrossRefPubMedCentralPubMed
24.
Grossman SA, Ellsworth S, Campian J et al (2015) Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J Natl Compr Cancer Netw 13:1225–1231CrossRef
25.
Grossman SA, Ye X, Lesser G et al (2011) Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 17:5473–5480CrossRefPubMedCentralPubMed
26.
Balmanoukian A, Ye X, Herman J et al (2012) The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Investig 30:571–576CrossRef
27.
Fang P, Jiang W, Davuluri R et al (2018) High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer. Radiother Oncol 128:584–590CrossRefPubMed
28.
Wild AT, Ye X, Ellsworth SG et al (2015) The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol 38:259–265CrossRefPubMedCentralPubMed
29.
Hollowell JG, van Assendelft OW, Gunter EW et al (2005) Hematological and iron-related analytes—reference data for persons aged 1 year and over: United States, 1988–94. Vital Health Stat 11 247:1–156
30.
Bain B, Seed M, Godsland I (1984) Normal values for peripheral blood white cell counts in women of four different ethnic origins. J Clin Pathol 37:188–193CrossRefPubMedCentralPubMed
31.
Onda T, Yoshikawa H, Yasugi T et al (2010) The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment. Jpn J Clin Oncol 40:36–41CrossRefPubMed
32.
Ghisoni E, Katsaros D, Maggiorotto F et al (2018) A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two-centers experience. J Ovarian Res 11:42CrossRefPubMedCentralPubMed
33.
Baek MH, Lee SW, Park JY et al (2017) Preoperative predictive factors for complete cytoreduction and survival outcome in epithelial ovarian, tubal, and peritoneal cancer after neoadjuvant chemotherapy. Int J Gynecol Cancer 27:420–429CrossRefPubMed
34.
Zeng J, Yin J, Song X et al (2016) Reduction of CA125 levels during neoadjuvant chemotherapy can predict cytoreduction to no visible residual disease in patients with advanced epithelial ovarian cancer, primary carcinoma of fallopian tube and peritoneal carcinoma. J Cancer 7:2327–2332CrossRefPubMedCentralPubMed
35.
Smith HA, Kang Y (2013) The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) 91:411–429CrossRef
Metadata
Title
Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer
Authors
Yasunori Yoshino
Ayumi Taguchi
Maki Takao
Tomoko Kashiyama
Akiko Furusawa
Masaya Uno
Satoshi Okada
Nao Kino
Toshiharu Yasugi
Publication date
01-04-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 4/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-018-1374-4

Other articles of this Issue 4/2019

International Journal of Clinical Oncology 4/2019 Go to the issue

Original Article

Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer

Original Article

Genetic association of promoter in GRP78 gene with nasopharyngeal carcinoma in a Chinese population

Original Article

Body composition as a predictor of toxicity after treatment with eribulin for advanced soft tissue sarcoma

Original Article

To what extent does the EQ-5D-3L correlate with the FACT-H&N of patients with oral cancer during the perioperative period?

Review Article

Survivin rs9904341 polymorphism significantly increased the risk of cancer: evidence from an updated meta-analysis of case–control studies

Original Article

The effects of intraoperative ICG fluorescence angiography in laparoscopic low anterior resection: a propensity score-matched study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits